HL08
/ Hualan Biological Engineering
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 04, 2026
Hualan Biological Engineering…announced that the National Medical Products Administration (NMPA) has approved a clinical trial for HL08, its next‑generation GLP‑1 receptor agonist, for a new indication in weight control for obese patients
(flcube.com)
- "Next Steps: Phase I/II obesity trial initiation expected Q2 2026."
New indication • New P1/2 trial • Obesity
1 to 1
Of
1
Go to page
1